| Literature DB >> 34909224 |
Olivier Courage1, Louise Strom2, Floris van Rooij2, Matthieu Lalevée1,3, Donatien Heuzé1,3, Pierre Emanuel Papin1,3, Michael Butnaru1,3, Jacobus Hendrik Müller2.
Abstract
The purpose of this systematic review was to synthesize studies published since the last systematic review in 2015 that compare outcomes of primary total knee arthroplasty (TKA) in older patients (≥ 80 years) and in younger patients (< 80 years), in terms of complication rates and mortality.An electronic literature search was conducted using PubMed, Embase®, and Cochrane Register. Studies were included if they compared outcomes of primary TKA for osteoarthritis in patients aged 80 years and over to patients aged under 80 years, in terms of complication rates, mortality, or patient-reported outcomes (PROs).Thirteen studies were eligible. Surgical complications in older patients ranged from 0.6-21.1%, while in younger patients they ranged from 0.3-14.6%. Wound complications in older patients ranged from 0.5-20%, while in younger patients they ranged from 0.8-22.0%. Medical complications (cardiac, respiratory, thromboembolic) in older patients ranged from 0.4-17.3%, while in younger patients they ranged from 0.2-11.5%.Mortality within 90 days in older patients ranged between 0-2%, while in younger patients it ranged between 0.0-0.03%.Compared to younger patients, older patients have higher rates of surgical and medical complications, as well as higher mortality following TKA. The literature also reports greater length of stay for older patients, but inconsistent findings regarding PROs. The present findings provide surgeons and older patients with clearer updated evidence, to make informed decisions regarding TKA, considering the risks and benefits within this age group. Patients aged over 80 years should therefore not be excluded from consideration for primary TKA based on age alone. Cite this article: EFORT Open Rev 2021;6:1052-1062. DOI: 10.1302/2058-5241.6.200150.Entities:
Keywords: TKA; elderly; geriatric; length of stay; mortality; nonagenarian; octogenarian; outcomes; total knee arthroplasty
Year: 2021 PMID: 34909224 PMCID: PMC8631241 DOI: 10.1302/2058-5241.6.200150
Source DB: PubMed Journal: EFORT Open Rev ISSN: 2058-5241
Study characteristics studies comparing patients aged > 80 and < 80 years following primary TKA
| Author and year | Groups | Patients | Female sex | Age mean [median] | BMI | ASA grade I | ASA grade II | ASA grade III | ASA grade IV | Location | COI declared | Funding declared |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Andreozzi et al 2020 | >80 years | 103 | 68% | 83 | 16% | 45% | 39% | Italy | Yes | Yes | ||
| <80 years | 103 | 68% | 64.6 | 43% | 52% | 5% | ||||||
| Austin et al 2018[ | >80 years | 175 | 56% | >80 | United States | Yes | Yes | |||||
| <80 years | 2133 | 58% | <80 | |||||||||
| Bovonratwet et al 2019[ | >80 years | 1005 | 53% | 82.8 | 28.5 | ASA 1 + 2: 44% | 51% | 2% | United States | Yes | Yes | |
| <80 years | 17191 | 51% | 64 | 32.2 | ASA 1 + 2: 59% | 40% | 1% | |||||
| Cher et al 2018[ | >80 years | 209 | 82.1 | 26.4 | Singapore | Yes | Yes | |||||
| <80 years | 209 | 66.1 | 26.6 | |||||||||
| Goh et al 2020[ | >80 years | 594 | 80% | 81.5 | 26.4 | Singapore | Yes | Yes | ||||
| <80 years | 594 | 80% | 69.7 | 26.3 | ||||||||
| Klasan et al 2019[ | >80 years | 644 | 64% | 83.3 | 3% | 49% | 47% | 0% | Australia | Yes | ||
| <80 years | 644 | 64% | 69.9 | 3% | 49% | 47% | 0% | |||||
| Kodaira et al 2019[ | >80 years | 679 | 77% | 82 | 25.1 | Japan | Yes | Yes | ||||
| <80 years | 673 | 81% | 71 | 27.0 | ||||||||
| Maempel et al 2015[ | >80 years | 358 | [83] | Scotland | Yes | |||||||
| 75–80 years | 694 | [77] | ||||||||||
| <75 years | 2092 | [66] | ||||||||||
| Murphy et al 2018[ | >80 years | 292 | 62% | 83 | 30.4 | 1% | 45% | 52% | 1% | Australia | Yes | Yes |
| <80 years | 2062 | 67% | 67.8 | 33.7 | 3% | 54% | 42% | 1% | ||||
| Sezgin et al 2019[ | >80 years | 22 | 92 | Sweden | ||||||||
| <80 years | 1035 | 65-74 | ||||||||||
| Skinner et al 2016[ | >80 years | 31 | 61% | 91 | 27.2 | England | ||||||
| <80 years | 36 | 36% | 74.56 | 26.1 | ||||||||
| Townsend et al 2018[ | >79 years | 24 | 54% | >79 | 29.0 | United States | Yes | |||||
| 70–79 years | 94 | 62% | 70–79 | 31.6 | ||||||||
| 60–69 years | 138 | 69% | 60–69 | 34.6 | ||||||||
| 50–59 years | 68 | 72% | 50–59 | 35.7 | ||||||||
| <50 years | 32 | 72% | <50 | 35.9 | ||||||||
| Yun et al 2018[ | >80 years | 38 | 84% | 82.8 | 25.6 | 0% | 61% | 34% | 5% | Republic of Korea | Yes | |
| <80 years | 41 | 92% | 67.9 | 25.8 | 0% | 61% | 39% | 0% |
Note. TKA, total knee arthroplasty; ASA, American Society of Anesthesiologists; BMI, body mass index; COI, conflict of interest.
Fig. 1Flowchart.
Note. TKA, total knee arthroplasty; THA, total hip arthroplasty.
Complications in patients aged > 80 and < 80 years following primary TKA
| Author | Groups | Surgical complications | Wound complications | Cardiac | Medical complications | Confusion/delirium | |
|---|---|---|---|---|---|---|---|
| Respiratory | Thromboembolic | ||||||
| Andreozzi et al 2020[ | >80 years | 10.00% | 4.00% | 6.00% | 12.00% | ||
| <80 years | 8.00% | 2.00% | 3.00% | 5.00% | |||
| Austin et al 2018[ | >80 years | ||||||
| <80 years | |||||||
| Bovontarwet et al 2019[ | >80 years | 0.50% | 1.44% | 0.40% | 1.29% | ||
| <80 years | 0.78% | 0.96% | 0.20% | 0.56% | |||
| Klasan et al 2019[ | >80 years | 2.44% | 2.00% | ||||
| <80 years | 2.27% | 2.00% | |||||
| Kodaira et al 2019[ | >80 years | 0.60% | 2.20% | 11.70% | |||
| <80 years | 0.30% | 2.20% | 1.60% | ||||
| Maempel et al 2015[ | >80 years | 1.70% | 3.10% | 1.60% | 0.90% | 3.10% | |
| 75–80 years | 2.00% | 1.60% | 2.30% | 0.60% | 2.20% | ||
| <75 years | 1.10% | 1.40% | 0.90% | 1.00% | 0.60% | ||
| Murphy et al 2018[ | >80 years | 20.00% | 17.30% | 3.30% | 13.10% | 11.10% | |
| <80 years | 22.00% | 11.50% | 1.90% | 9.40% | 2.60% | ||
| Yun et al 2018[ | >80 years | 21.10% | 10.50% | ||||
| <80 years | 14.60% | 4.90% | |||||
Note. TKA, total knee arthroplasty.
Fig. 2Forest plot of the risk difference (RD) of surgical complications in patients aged > 80 years and < 80 years (a RD of 0.02 corresponds to a 2% higher risk for patients aged > 80).
Fig. 3Forest plot of the risk difference (RD) of medical complications in patients aged > 80 years and < 80 years (a RD of 0.02 corresponds to a 2% higher risk for patients aged > 80).
Mortality in patients aged > 80 and < 80 years following primary TKA
| Author and date | Groups | Time | Mortality | p-value |
|---|---|---|---|---|
| Andreozzi et al 2020[ | >80 years | Within 90 days | 2.00% | |
| <80 years | 0.00% | |||
| Bovonratwet et al 2019[ | >80 years | Within 90 days | 0.20% | 0.108 |
| <80 years | 0.03% | |||
| Klasan et al 2019[ | >80 years | Within 10 years | 32.00% | <0.001 |
| <80 years | 12.00% | |||
| Maempel et al 2015[ | >80 years | Within 1 year | 3.20% | |
| 75–80 years | 2.00% | |||
| <75 years | 1.50% | |||
| Murphy et al 2018[ | >80 years | Within 10 years | 28.00% | |
| <80 years | 7.00% | |||
| Skinner et al 2016[ | >80 years | Within 2 years | 12.90% | |
| <80 years | 0.00% | |||
| Yun et al 2018[ | >80 years | Within 90 days | 0.00% | |
| <80 years | 0.00% |
Note. TKA, total knee arthroplasty.
Length of stay (LoS) in patients aged > 80 and < 80 years following primary TKA
| Author | Groups | LoS | p-value |
|---|---|---|---|
| Andreozzi et al 2020[ | >80 years | 5.8 | <0.001 |
| <80 years | 4.1 | ||
| Austin et al 2018[ | >80 years | 3.3 | |
| <80 years | 2.9 | ||
| Kodaira et al 2019[ | >80 years | 18.8 | |
| <80 years | 16.8 | ||
| Murphy et al 2018[ | >80 years | [5] | |
| <80 years | [4] | ||
| Sezgin et al 2019[ | >80 years | 6.2 | |
| <80 years | 4.1 | ||
| Skinner et al 2016[ | >80 years | 8.4 | 0.001 |
| <80 years | 5.6 | ||
| Townsend et al 2018[ | >79 years | 2.0 | 0.318 |
| 70–79 years | 1.7 | ||
| 60–69 years | 1.5 | ||
| 50–59 years | 1.9 | ||
| <50 years | 1.6 | ||
| Yun et al 2018[ | >80 years | 20.9 | <0.001 |
| <80 years | 14.4 |
Note. TKA, total knee arthroplasty.
Clinical outcomes comparing patients aged > 80 and < 80 years following primary TKA
| Author | Patient-reported outcome | >80 | Comparator | p-value | Patient-reported outcomecomparison | ||
|---|---|---|---|---|---|---|---|
| Mean | ± | Mean(range | ± | ||||
| Andreozzi et al 2020[ | OKS | 40 | 2.6 | 41 | 2.7 | No difference | |
| KSS | 81.5 | 9.6 | 83.3 | 6.8 | No difference | ||
| KSFS | 77.6 | 7.6 | 83.2 | 8.8 | 0.122 | No difference | |
| Austin et al 2018[ | PCS | Not reported | Not reported | No difference | |||
| Cher et al 2018[ | OKS | 22.85 | 19.98 | No difference | |||
| KSS | 84.4 | 86.2 | No difference | ||||
| KSFS | 55.77 | 73.44 | No difference | ||||
| SF-36 | 49.59 | 46.41 | <0.05 | Better for >80 | |||
| Goh et al 2020[ | OKS | 39.2 | 6.7 | 41.5 | 5.2 | <0.001 | Worse for >80 |
| KSS | 83.1 | 12.3 | 82.2 | 11.9 | No difference | ||
| KSFS | 57.7 | 19.6 | 69.8 | 19 | <0.001 | Worse for >80 | |
| SF-36 PCS | 45.2 | 11.1 | 48.1 | 10 | 0.001 | Worse for >80 | |
| SF-36 MCS | 55 | 10.2 | 55.5 | 10.2 | No difference | ||
| Klasan et al 2019[ | OKS | 38.9 | 41 | <0.001 | Worse for >80 | ||
| Kodaira et al 2019[ | JOA | 82.8 | 0.4 | 87.4 | 0.3 | No difference | |
| Maempel et al 2015[ | AKSK | 93[ | (92–93)[ | 0.001 | Better for >80 | ||
| AKSF | 65 | 80–80 | <0.001 | Worse for >80 | |||
| Murphy et al 2018[ | SF-12 PCS | No difference | |||||
| Sezgin et al 2019[ | KOOS | 0.005 (symptoms) | Better for >80 | ||||
| (KOOS symptoms) | |||||||
| EQ-VAS | 76 | 78 | 0.700 | No difference | |||
| Skinner et al 2016[ | OKS | n.s. | No difference | ||||
| Townsend et al 2018[ | WOMAC | 63.5 | (53.0–64.4) | No difference | |||
| OKS | 26.5 | (23.0–27.8) | No difference | ||||
| Yun et al 2018[ | WOMAC | 28.7 | 21.7 | 0.009 | Worse for >80 | ||
| KSS | 68.34 | 64.83 | 0.130 | No difference | |||
| SF-36 | 51.3 | 59.5 | 0.022 | Worse for >80 | |||
Note. TKA, total knee arthroplasty; OKS, Oxford Knee Score; KSS, Knee Society Score; KSFS, Knee Society Score (Function); KOOS, Knee injury and Osteoarthritis Outcome Score; JOA, Japanese Orthopaedic Association;
AKSK, American Knee Society Score (Knee); AKSF, American Knee Society Score (Function); PCS, Physical Component Socre; MCS, Mental Component Score; EQ-VAS, EuroQol Visual Analogue Scale; SF-36, Short Form 36; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
*The range is reported in case of multiple comparator groups.
Median values.
Assessment of methodological quality of clinical studies using an modified version of the checklist by Downs and Black
| Author and year | Evaluated domain | Total (/28) | Total (%) | ||||
|---|---|---|---|---|---|---|---|
| Internal validity | |||||||
| Reporting | External validity | Study bias | Selection bias | Power | |||
| (/11) | (/3) | (/7) | (/6) | (/1) | |||
| Andreozzi et al 2020[ | 10 | 0 | 6 | 2 | 1 | 19 | 68% |
| Austin et al 2018[ | 11 | 2 | 5 | 3 | 0 | 21 | 75% |
| Bovonratwet et al 2019[ | 8 | 2 | 5 | 2 | 0 | 17 | 61% |
| Cher et al 2018[ | 10 | 1 | 5 | 2 | 1 | 19 | 68% |
| Goh et al 2020[ | 9 | 1 | 5 | 3 | 1 | 19 | 68% |
| Klasan et al 2019[ | 8 | 1 | 4 | 2 | 1 | 16 | 57% |
| Kodaira et al 2019[ | 7 | 1 | 4 | 2 | 0 | 14 | 50% |
| Maempel et al 2015[ | 7 | 2 | 5 | 3 | 0 | 17 | 61% |
| Murphy et al 2018[ | 9 | 2 | 5 | 4 | 1 | 21 | 75% |
| Sezgin et al 2019[ | 7 | 2 | 5 | 1 | 0 | 15 | 54% |
| Skinner et al 2016[ | 10 | 1 | 4 | 2 | 0 | 17 | 61% |
| Townsend et al 2018[ | 8 | 2 | 4 | 3 | 0 | 17 | 61% |
| Yun et al 2018[ | 10 | 1 | 4 | 3 | 0 | 18 | 64% |